Ignite Creation Date:
2024-05-06 @ 8:38 AM
Last Modification Date:
2024-10-26 @ 12:03 PM
Study NCT ID:
NCT02784808
Status:
COMPLETED
Last Update Posted:
2016-06-08
First Post:
2016-05-25
Brief Title:
Retrospective Analysis of Pulmonary Arterial Hypertension PAH and Related Complications in Juvenile Idiopathic Arthritis JIA Participants Treated With Biologic and Non-biologic Disease-modifying Anti-rheumatic Drugs DMARDs
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2016-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to analyze the frequency and incidence rate of pulmonary complications in JIA participants who received biological DMARDs and non-biologic DMARDs The participants having evidence of of a prescription or administration of one of the biologic or non-biologic DMARDs will be included in five different treatment groups Data from the Thomson Reuters MarketScan Commercial Claims and Medicare Supplemental Databases will be used to estimate the incidence rate of pulmonary complications
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None